Loading...
01/10 16:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows strong financial performance with increased EPS and revenue, but concerns arise from declining gross margins and competitive pressures in key markets like China. The Q&A highlights tariff impacts and capital budget constraints, offsetting the positive momentum from procedure volume guidance. No shareholder return plans were discussed, keeping the sentiment neutral. Without a market cap, the stock's reaction is uncertain, but the mixed signals suggest a neutral movement in the stock price over the next two weeks.
EPS $1.81, up from $1.50, a 21% increase year-over-year.
Revenue $2.25 billion, a 19% increase year-over-year, driven by strong procedure growth and higher system placements.
Systems Revenue Increased by 25% year-over-year, driven by a 17% increase in da Vinci system placements and higher average selling prices.
Recurring Revenue Grew 19% in Q1, representing 85% of total revenue.
Average Selling Price (ASP) $1.62 million, up from $1.39 million last year, primarily due to a higher mix of da Vinci 5 placements.
Pro forma Gross Margin 66.4%, down from 67.6% year-over-year, primarily due to higher facilities costs and a higher mix of lower-margin products.
Operating Expenses Increased by 12% year-over-year, driven by increased headcount and higher facilities-related costs.
Net Income $662 million, or $1.81 per share, compared to $541 million, or $1.50 per share, for the same quarter last year.
Cash and Investments $9.1 billion, up from $8.8 billion at the end of last year.
Capital Expenditures $117 million in Q1.
Ion Procedures Approximately 31,000, an increase of 58% year-over-year.
SP Procedures Grew 94% year-over-year.
System Placements 367 systems placed in Q1, a 17% increase from 313 systems placed in the same period last year.
da Vinci 5 System Rollout: In Q1, the rollout of da Vinci 5 progressed within expectations with 147 systems placed and over 32,000 procedures performed across a broad set of specialties.
SP Platform Growth: SP procedure growth accelerated in the quarter to 94%, with solid growth in the U.S. and OUS procedures more than doubling compared to the year ago period.
Ion Platform Expansion: In April, we received clearance of our Ion platform in Australia and our first provincial charge code in China.
Procedure Growth: Da Vinci procedure growth in the quarter was 17%, with strong performance in general surgery in the U.S. and regional performance in India, Korea, and the U.K.
International Market Performance: Procedure growth in OUS markets grew 24%, driven by strength in India, Korea, distributor markets, and the U.K.
Manufacturing Expansion: Opened two new facilities at our Sunnyvale, California headquarters, expanding U.S. manufacturing and R&D footprint significantly.
Headcount Increase: Increased headcount by over 500 employees, with approximately half in manufacturing roles to support revenue growth.
Supply Chain Strategy: Adjustments to supply chain strategy will be assessed as trade policies stabilize, with a focus on optimizing production costs.
Pricing Strategy: No reflexive changes to pricing are planned in the near-term dynamic environment.
Trade Policy Risks: Dynamic changes in trade policy may affect product supply and pricing strategies. The company plans to adjust its supply chain strategy and pricing based on the stability of trade policies.
Tariff Impact: Tariffs on imports from China and other regions are expected to increase costs, with an estimated impact of approximately 1.7% of revenue in 2025. This includes 125% tariffs on certain imports into China and 145% tariffs on components from Chinese suppliers.
Regulatory Challenges: The company is navigating regulatory processes in Japan and expects clearance in Europe by the end of 2025, which may affect market access and product launches.
Supply Chain Challenges: The company is focused on optimizing production costs and rebalancing product flows within its manufacturing and supply chain to mitigate risks associated with tariffs and trade policies.
Economic Pressures: Financial pressures faced by hospitals and constraints on capital budgets in key markets (e.g., Japan, Germany, U.K.) may lead to customers reprioritizing capital investments in robotic programs.
Competitive Pressures: In China, domestic competition and policy-driven pricing pressures may adversely impact the company's ability to win future tenders.
Product Supply and Pricing Strategy: Intuitive Surgical prioritizes ensuring the supply of products globally and does not plan reflexive changes to pricing in the near-term due to dynamic trade policies.
Manufacturing Optimization: The company aims to optimize production costs and rebalance product flows within its existing manufacturing and supply chain footprint.
Launch of da Vinci 5: The full launch of da Vinci 5 is a key priority, with expectations for regional clearances and follow-on feature releases.
Expansion of Digital Tools: Focus on excellence and availability of digital tools to enhance surgical performance.
International Market Expansion: Priorities include supporting utilization growth in the U.S. and expanding in international markets.
Procedure Growth: Full year 2025 procedure growth is now expected to be within a range of 15% to 17%.
Gross Margin: Pro forma gross margin is updated to be within the range of 65% to 66.5% of revenue due to tariff impacts.
Operating Expenses: Pro forma operating expense growth is now expected to be between 10% and 14%.
Capital Expenditures: Estimated capital expenditures for 2025 are projected to be between $650 million and $750 million.
Income Tax Rate: Estimated pro forma income tax rate for 2025 is between 22% and 23% of pre-tax income.
Share Buyback Program: Intuitive Surgical did not mention any share buyback program during the call.
Dividend Program: Intuitive Surgical did not discuss any dividend program during the call.
The earnings call highlights strong growth in procedure volumes and successful adoption of the da Vinci 5 system, indicating positive market reception. Despite challenges in the bariatric and China markets, guidance updates reflect strategic adaptability. The Q&A section provides additional insights into growth areas like alternative care sites and new platforms, supporting a positive outlook. However, management's lack of clarity on certain issues tempers the sentiment slightly. Overall, the combination of strong financial performance, strategic initiatives, and positive guidance adjustments suggests a positive stock price movement.
The earnings call highlights strong financial performance with increased revenue and net income, despite a slight decline in gross margin. The company shows strong growth in system utilization and procedures, particularly for SP and Ion systems. The Q&A section reveals positive sentiment towards future product enhancements and market expansion, although some concerns about Medicaid changes and trade-in financials were noted. The company's focus on innovation and strategic share repurchases further supports a positive outlook. Overall, these factors suggest a positive stock price movement in the near term.
The earnings call shows strong financial performance with increased EPS and revenue, but concerns arise from declining gross margins and competitive pressures in key markets like China. The Q&A highlights tariff impacts and capital budget constraints, offsetting the positive momentum from procedure volume guidance. No shareholder return plans were discussed, keeping the sentiment neutral. Without a market cap, the stock's reaction is uncertain, but the mixed signals suggest a neutral movement in the stock price over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
